SEER is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
Code grade specified by pathologist. If no grade specified, code 9
This is a neoplasm with diffuse proliferation of large neoplastic cells, most of which resemble B immunoblasts, but in which all tumor cells have the immunophenotype of plasma cells. This disease is uncommon. The highest percentage occurs in patients who are HIV positive.
(This code is effective for cases diagnosed 2010 and later. For cases diagnosed prior to 2010, see code 9684/3.)
PBL is uncommon. The highest incidence is in HIV-positive individuals.
Most patients present at Stages III/IV. The international prognostic index (IPI) is of intermediate to high risk.
EBV positivity is seen in the majority of patients.
Definitive Diagnostic Methods
Clonal IgH light chain rearrangement
CD20 weakly positive
CD45 weakly positive
CD56- in oral mucosal primary
Cytoplasmic immunoglobulins expressed, most frequently IgG and either kappa or lambda light chain